title: The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China.
abstract: OBJECTIVE
  This study sought to determine whether postoperative hormone replacement therapy (HRT) has a negative influence on the progression-free and overall survival of epithelial ovarian carcinoma patients.
  
  
  METHODS
  A retrospective chart review identified 77 patients with invasive epithelial ovarian cancer who had received HRT after primary surgical treatment from January 1995 to December 2010 at Peking Union Medical College Hospital. A 1 : 1 cohort of patients with the same diagnosis who did not receive HRT were matched by age and stage. An analysis of both progression-free survival and overall survival was performed using Cox proportional hazards models.
  
  
  RESULTS
  According to the univariate analysis, HRT did not significantly influence progression-free or overall survival. Similarly, different types of HRT (estrogen alone, tibolone alone or an estrogen-tibolone combination) had no significant effect on the prognosis of epithelial ovarian cancer patients. The FIGO stage, differentiation, histological type and resection status were significantly correlated with progression-free survival and, except for histological type, these factors also significantly influenced overall survival. Finally, the multivariate analysis demonstrated that the strongest independent variable in predicting both progression-free survival and overall survival was the FIGO stage of the disease.
  
  
  CONCLUSIONS
  This study supports the hypothesis that postoperative HRT does not have a negative effect on the progression-free and overall survival of epithelial ovarian cancer patients. However, a multicenter study is needed to support and extend our findings.
authors.affiliation: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , P. R. China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wen
authors.forename: H
authors.initials: H
authors.lastname: Huang
authors.forename: H
authors.initials: H
authors.lastname: Huang
authors.forename: M
authors.initials: M
authors.lastname: Wu
authors.forename: K
authors.initials: K
authors.lastname: Shen
authors.forename: L
authors.initials: L
authors.lastname: Pan
mesh_terms: D000293:Adolescent; D000328:Adult; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D002681:China; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination / Q000009:adverse effects; D020847:Estrogen Receptor Modulators / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008594:Menopause, Premature; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000473:pathology* / Q000601:surgery*; D009652:Norpregnenes / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000601:surgery*; D011184:Postoperative Period; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D020847:Estrogen Receptor Modulators; D004967:Estrogens; D009652:Norpregnenes; C027385:tibolone